Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclooxygenase-2 selective inhibitors.

G W Cannon1

  • 1Salt Lake City VA Medical Center, Salt Lake City, Utah 84148, USA.

Drugs of Today (Barcelona, Spain : 1998)
|September 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis<sup>✰</sup>.

Seminars in arthritis and rheumatism·2019
Same author

A comparison of electronic and manual fracture risk assessment tools in screening elderly male US veterans at risk for osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Arthritis care & research·2014
Same author

Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Clinical and experimental rheumatology·2014
Same author

Poor to modest agreement between rheumatoid arthritis response measures in clinical practice.

Clinical and experimental rheumatology·2009
Same journal

Monoclonal antibodies for treatment of osteoporosis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Sugemalimab, a novel PD-L1 inhibitor for treatment of advanced or metastatic non-small cell lung cancer.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Secukinumab, ixekizumab, bimekizumab and brodalumab for psoriasis and psoriatic arthritis.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Mitapivat for sickle cell disease and thalassemia.

Drugs of today (Barcelona, Spain : 1998)·2023
Same journal

Cenegermin for the treatment of dry eye disease.

Drugs of today (Barcelona, Spain : 1998)·2023
See all related articles

New cyclooxygenase-2 (COX-2) selective inhibitors offer similar efficacy to traditional nonsteroidal anti-inflammatory drugs (NSAIDs) but with fewer gastrointestinal side effects. These COX-2 inhibitors target inflammation without inhibiting COX-1 housekeeping functions.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Inflammation Research

Background:

  • Two cyclooxygenase (COX) enzymes, COX-1 and COX-2, are crucial for understanding prostaglandin roles in inflammation.
  • COX-1 is involved in constitutive functions (gastric mucosa, kidney, platelets), while COX-2 is inducible and promotes inflammatory actions.
  • Traditional nonsteroidal anti-inflammatory drugs (NSAIDs) inhibit both COX-1 and COX-2, leading to therapeutic benefits (via COX-2 inhibition) and adverse effects (via COX-1 inhibition), particularly gastrointestinal toxicity.

Purpose of the Study:

  • To evaluate the potential of newly developed COX-2 selective inhibitors.
  • To compare the efficacy and toxicity profiles of COX-2 selective inhibitors against traditional NSAIDs.
  • To determine if selective COX-2 inhibition can provide anti-inflammatory benefits with reduced side effects.

Related Experiment Videos

Main Methods:

  • Review of current data on COX-2 selective inhibitors.
  • Analysis of the mechanisms of action for COX-1 and COX-2 enzymes.
  • Comparison of clinical outcomes and side effect profiles between selective COX-2 inhibitors and traditional NSAIDs.

Main Results:

  • COX-2 selective inhibitors demonstrate efficacy comparable to standard NSAIDs.
  • Selective inhibition of COX-2 may lead to reduced gastrointestinal toxicity compared to non-selective NSAIDs.
  • The therapeutic benefits of NSAIDs are primarily linked to COX-2 inhibition.

Conclusions:

  • COX-2 selective inhibitors represent a promising therapeutic option for managing inflammation.
  • These agents offer a potentially improved safety profile by avoiding COX-1 inhibition.
  • Selective COX-2 inhibitors are expected to provide similar clinical efficacy to traditional NSAIDs with fewer adverse effects.